Form 4: Phio CFO Lisa Carson Granted 47,000 Restricted Stock Units

Phio Pharmaceuticals Corp.'s Chief Financial Officer, Lisa Cabott Carson, was granted 47,000 restricted stock units, vesting on the first anniversary of the grant date.

Summary

• Lisa Cabott Carson, Chief Financial Officer of Phio Pharmaceuticals Corp., acquired 47,000 shares of common stock.
• These shares represent restricted stock units (RSUs) granted on February 5, 2026.
• The RSUs will vest on the first annual anniversary of the grant date.
• Following this transaction, Ms. Carson beneficially owns 94,000 shares, which include these new RSUs and previously unvested restricted stock units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with long-term company performance.

Positives

• The grant of 47,000 restricted stock units to the Chief Financial Officer aligns management's interests with shareholder value.

Future Outlook

The 47,000 restricted stock units granted to the CFO are scheduled to vest on the first annual anniversary of the grant date, February 5, 2026.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the CFO are a standard practice in the biotechnology and pharmaceutical industry, often used to incentivize long-term performance and retain talent. This aligns the executive's financial interests with the company's stock performance, a common strategy among peers such as Moderna or BioNTech.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a Chief Financial Officer is a common compensation practice across the biotechnology and pharmaceutical sectors, comparable to similar equity incentive programs at companies like Gilead Sciences or Amgen, which frequently use RSUs to tie executive compensation to long-term shareholder value creation.
• The vesting schedule, typically over several years or on an annual anniversary, is also standard, aiming to retain key personnel and encourage sustained performance, mirroring practices seen in executive compensation packages at Pfizer or Johnson & Johnson.

Stakeholder Impact

• Shareholders: Potential for improved alignment of management interests with shareholder value through equity incentives.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent for other equity-based incentives.

Next Steps

• The 47,000 restricted stock units are scheduled to vest on February 5, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. While positive for corporate governance and executive retention, it does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation based solely on this disclosure. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Phio Pharmaceuticals, PHIO, Form 4, RSU, Restricted Stock Unit, Insider Transaction, Lisa Cabott Carson, CFO, Equity Grant